Omeros (NASDAQ:OMER – Get Free Report) is scheduled to release its earnings data after the market closes on Wednesday, November 13th.
Omeros Trading Down 2.7 %
Shares of NASDAQ OMER opened at $4.29 on Tuesday. The firm has a fifty day simple moving average of $4.01 and a two-hundred day simple moving average of $4.04. Omeros has a 12 month low of $1.17 and a 12 month high of $5.68. The firm has a market capitalization of $248.59 million, a PE ratio of -1.83 and a beta of 1.47.
Analysts Set New Price Targets
Separately, StockNews.com upgraded Omeros from a “sell” rating to a “hold” rating in a research report on Friday, August 16th.
Omeros Company Profile
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.
Featured Stories
- Five stocks we like better than Omeros
- What is a Stock Market Index and How Do You Use Them?
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- How to Effectively Use the MarketBeat Ratings Screener
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
- Basic Materials Stocks Investing
- These 3 Active ETFs Beat the S&P 500 Over the Last Five Years
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.
